Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 6/20 | 0.49 |
| ▸ | FPR3 | P25089 | 3/20 | 0.47 |
| ▸ | RORC | P51449 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15675293 | 1.00 | FPR2 (0.49) | FPR2FPR3RORCMAPTCHRNA7 | |
| SCHEMBL14375625 | 1.00 | FPR2 (0.49) | FPR2FPR3RORCMAPTCHRNA7 | |
| SCHEMBL21199337 | 0.88 | MEN1 (0.47) | RORCMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL14335737 | 0.85 | L3MBTL1 (0.41) | MAPTCHRNA7MEN1ALDH1A1KMT2A | |
| SCHEMBL14335739 | 0.85 | L3MBTL1 (0.41) | MAPTCHRNA7MEN1ALDH1A1KMT2A | |
| SCHEMBL14335736 | 0.85 | L3MBTL1 (0.41) | MAPTCHRNA7MEN1ALDH1A1KMT2A | |
| SCHEMBL3616230 | 0.81 | STS (0.48) | MAPTMEN1KMT2AUSP30 | |
| SCHEMBL3616231 | 0.81 | STS (0.48) | MAPTMEN1KMT2AUSP30 | |
| SCHEMBL13502918 | 0.81 | STS (0.48) | MAPTMEN1KMT2AUSP30 | |
| SCHEMBL1673620 | 0.80 | FPR2 (0.55) | FPR2FPR3RORCMAPTCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721008-B1 | HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES AS P53 (MDM2 OR MDM4) INHIBITORS | NOVARTIS AG (CH) | 2015-04-29 | — | — | EP | disclosed |
| US-8859535-B2 | Hydroxy substituted isoquinolinone derivatives | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| US-20140135306-A1 | HDYROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135306-A1 | HDYROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES | MDM4, MDM2, TP53 | FPR2 3627/4885FPR3 3629/4885RORC 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.